JPRN-UMIN000009042招募中2 期
Phase II study of bortezomib-melphalan-prednisolone induction therapy followed by lenalidomide-plus-dexamethasone consolidation and lenalidomide maintenance for newly diagnosed patients with multiple myeloma ineligible for stem cell transplantation. - Consolidation AND long-term management by LEnalidomide: CANDLE STUDY / J-MEN 04 STUDY
Japan Myeloma Expert Network (J-MEN) of Japan Myeloma Network (JMN)0 个研究点目标入组 80 人开始时间: 2012年10月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Women in pregnancy or lactation 2) plasma cell leukemia, cardiac amyloidosis, POEMS syndrome 3) Peripheral neuropathy Grade >=2 4) Uncontrolled liver dysfunction, renal dysfunction, heart failure, impaired respiratory function, diabetes, or hyper tension 5) Concurrent diseases of tuberculosis, herpes simplex keratitis, systemic fungal disease, or active infection 6) Postcapsular cataract 7) Recent operation history 8) Myocardial infarction in past 6 months or deep vein thrombosis / pulmonary embolism within 3 months 9) Active and advanced cancer (simultaneous or within 5 years after remission) 10) Positive for hepatitis B antigen, hepatitis C antibody, or HIV antibody 11) Concurrent pneumonitis (interstitial pneumonia), lung fibrosis, or abnormal (high-resolution) chest CT findings in both lung with/without symptom 12) The patient judged inappropriate to participate in this study
研究者
相似试验
进行中（未招募）
1 期
Attempt of treatment optimization in patients with untreated multiple myeloma not eligible to high-dose chemotherapy and autologous stem cell transplantation. After a cyclic treatment with Melphalan, Prednisone and Bortezomib (VMP) one group of patients will be treated with Revlimid, the other group will be treated with a placebo.MedDRA version: 19.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864multiple myelomaEUCTR2012-003023-38-DEFriedrich-Schiller-Universität Jena290
已完成
1 期
Phase I/II study of bortezomib plus Lenalidomide and dexamethasone (Once weekly VRd-21) for relapsed and/or refractory multiple myeloma (Once weekly VRd-21, I/II VRD for MM)Proteasome inhibitor and immunomodulatory drug pre-treated relapsed and/or refractory multiple myeloma after two or more prior lines of chemotherapyJPRN-UMIN000013169agoya City University Hospital30
招募中
2 期
A Phase II trial of bortezomib and dexamethasone in renally-impaired patients with untreated multiple myeloma.ACTRN12611000605998Prof. Andrew Spencer28
已完成
不适用
A phase 2 study of bortezomib, lenalidomide and dexamethasone (VRD) following auto-PBSCT for untreated multiple myeloma.Multiple myelomaJPRN-UMIN000026324Ochanomizu Hematology Study Group32
进行中（未招募）
1 期
Induction therapy with bortezomib-melphalan and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide and dexamethasone plus/minus daratumumab, 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: trial for elderly fit newly diagnosed multiple myeloma patients aged between 65 and 80 yearsMultiple myelomaEUCTR2017-000044-18-ESFundación PETHEMA462